In this article we discuss the challenges for manufacturers of therapeutics and diagnostics as they pursue the potential of companion diagnostics. Click below to read the article.
An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...